Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance

被引:8
作者
Baldursdottir, Theodora Run [1 ]
Love, Thorvardur Jon [1 ,2 ]
Gislason, Gauti Kjartan [2 ]
Bjorkholm, Magnus [3 ,4 ]
Mellqvist, Ulf-Henrik [5 ]
Lund, Sigrun Helga [2 ]
Blimark, Cecilie Hveding [6 ]
Turesson, Ingemar [7 ]
Hultcrantz, Malin [3 ,4 ,8 ]
Landgren, Ola [9 ]
Kristinsson, Sigurdur Yngvi [1 ,2 ]
机构
[1] Natl Univ Hosp Reykjavik, Landspitali, Reykjavik, Iceland
[2] Univ Iceland, Fac Med, Sturlugata 8, IS-101 Reykjavik, Iceland
[3] Karolinska Univ Hosp, Dept Med, Div Hematol, Stockholm, Sweden
[4] Karolinska Inst, Stockholm, Sweden
[5] South Elvsborg Hosp, Hematol, Boras, Sweden
[6] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden
[7] Skane Univ Hosp, Malmo, Sweden
[8] Mem Sloan Kettering Canc Ctr, Myeloma Serv, Div Hematol Oncol, 1275 York Ave, New York, NY 10021 USA
[9] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA
基金
欧盟地平线“2020”;
关键词
autoimmune disease; lymphoproliferative; monoclonal gammopathy of undetermined significance; multiple myeloma; population‐ based; PRECEDES MULTIPLE-MYELOMA; SIGNIFICANCE MGUS; HODGKIN-LYMPHOMA; LONG-TERM; FOLLOW-UP; PREVALENCE; DISORDERS; MALIGNANCIES; HISTORY;
D O I
10.1111/ejh.13563
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives and methods We conducted a population-based study including 19 303 individuals diagnosed with MGUS in Sweden from 1985 to 2013, with the aim to determine whether a prior history of autoimmune disease, a well-described risk factor for MGUS is a risk factor for progression of MGUS to multiple myeloma (MM) or lymphoproliferative diseases (LPs). Using the nationwide Swedish Patient registry, we identified MGUS cases with versus without an autoimmune disease present at the time of MGUS diagnosis and estimated their risk of progression. Results A total of 5612 (29.1%) MGUS cases had preceding autoimmune diseases. Using Cox proportional hazards models, we found the risk of progression from MGUS to MM (HR = 0.83, 95% CI 0.73-0.94) and LPs (HR = 0.84, 95% CI 0.75-0.94) to be significantly lower in MGUS cases with prior autoimmune disease (compared to MGUS cases without). Conclusions In this large population-based study, a history of autoimmune disease was associated with a reduced risk of progression from MGUS to MM/other LPs. Potential underlying reason is that MGUS caused by chronic antigen stimulation is biologically less likely to undergo the genetic events that trigger progression. Our results may have implications in clinical counseling for patients with MGUS and underlying autoimmune disease.
引用
收藏
页码:380 / 388
页数:9
相关论文
共 30 条
  • [1] Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders
    Brown, Linda Morris
    Gridley, Gloria
    Check, David
    Landgren, Ola
    [J]. BLOOD, 2008, 111 (07) : 3388 - 3394
  • [2] Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    Cesana, C
    Klersy, C
    Barbarano, L
    Nosari, AM
    Crugnola, M
    Pungolino, E
    Gargantini, L
    Granata, S
    Valentini, M
    Morra, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1625 - 1634
  • [3] Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Dispenzieri, Angela
    Katzmann, Jerry A.
    Kyle, Robert A.
    Larson, Dirk R.
    Melton, L. Joseph, III
    Colby, Colin L.
    Therneau, Terry M.
    Clark, Raynell
    Kumar, Shaji K.
    Bradwell, Arthur
    Fonseca, Rafael
    Jelinek, D. F.
    Rajkumar, S. Vincent
    [J]. LANCET, 2010, 375 (9727) : 1721 - 1728
  • [4] Prevalence of monoclonal gammopathy of undetermined significance: Study of 52,802 persons in Nagasaki city, Japan
    Iwanaga, Masako
    Tagawa, Masuko
    Tsukasaki, Kunihiro
    Kamihira, Shimera
    Tomonaga, Masao
    [J]. MAYO CLINIC PROCEEDINGS, 2007, 82 (12) : 1474 - 1479
  • [5] Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom Macroglobulinemia
    Kristinsson, Sigurdur Y.
    Koshiol, Jill
    Bjorkholm, Magnus
    Goldin, Lynn R.
    McMaster, Mary L.
    Turesson, Ingemar
    Landgren, Ola
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (08): : 557 - 567
  • [6] Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
    Kristinsson, Sigurdur Y.
    Goldin, Lynn R.
    Bjorkholm, Magnus
    Koshiol, Jill
    Turesson, Ingemar
    Landgren, Ola
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11): : 1581 - 1589
  • [7] Autoimmunity and risk for Hodgkin's lymphoma by subtype
    Kristinsson, Sigurdur Y.
    Landgren, Ola
    Sjoberg, Jan
    Turesson, Ingemar
    Bjorkholm, Magnus
    Goldin, Lynn R.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1468 - 1469
  • [8] Kwok M, 2012, J CLIN ONCOL, V30
  • [9] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    Kyle, R. A.
    Durie, B. G. M.
    Rajkumar, S. V.
    Landgren, O.
    Blade, J.
    Merlini, G.
    Kroeger, N.
    Einsele, H.
    Vesole, D. H.
    Dimopoulos, M.
    San Miguel, J.
    Avet-Loiseau, H.
    Hajek, R.
    Chen, W. M.
    Anderson, K. C.
    Ludwig, H.
    Sonneveld, P.
    Pavlovsky, S.
    Palumbo, A.
    Richardson, P. G.
    Barlogie, B.
    Greipp, P.
    Vescio, R.
    Turesson, I.
    Westin, J.
    Boccadoro, M.
    [J]. LEUKEMIA, 2010, 24 (06) : 1121 - 1127
  • [10] A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, MF
    Melton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 564 - 569